These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 35477416)

  • 1. Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy.
    Wu HL; Gong Y; Ji P; Xie YF; Jiang YZ; Liu GY
    J Hematol Oncol; 2022 Apr; 15(1):45. PubMed ID: 35477416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed.
    Abu Eid R; Razavi GS; Mkrtichyan M; Janik J; Khleif SN
    Cancer Immunol Res; 2016 May; 4(5):377-82. PubMed ID: 27196429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the DNA damage response in immuno-oncology: developments and opportunities.
    Chabanon RM; Rouanne M; Lord CJ; Soria JC; Pasero P; Postel-Vinay S
    Nat Rev Cancer; 2021 Nov; 21(11):701-717. PubMed ID: 34376827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical pharmacology of anticancer agents [Part 5] Antimetabolites (2)].
    Nakamura T; Ueda T; Uchida M
    Gan To Kagaku Ryoho; 1992 Mar; 19(3):409-20. PubMed ID: 1543370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific targeting of cancer stem cells by immunotherapy: A possible stratagem to restrain cancer recurrence and metastasis.
    Singh D; Khan MA; Siddique HR
    Biochem Pharmacol; 2022 Apr; 198():114955. PubMed ID: 35181312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation.
    Hatse S; De Clercq E; Balzarini J
    Biochem Pharmacol; 1999 Aug; 58(4):539-55. PubMed ID: 10413291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response.
    Ariav Y; Ch'ng JH; Christofk HR; Ron-Harel N; Erez A
    Sci Adv; 2021 May; 7(21):. PubMed ID: 34138729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionalized chitosan as a promising platform for cancer immunotherapy: A review.
    Liang X; Mu M; Fan R; Zou B; Guo G
    Carbohydr Polym; 2022 Aug; 290():119452. PubMed ID: 35550761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy.
    Sheppard AD; Lysaght J
    Methods Mol Biol; 2020; 2184():233-263. PubMed ID: 32808230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.
    Kapp K; Volz B; Curran MA; Oswald D; Wittig B; Schmidt M
    J Immunother Cancer; 2019 Jan; 7(1):5. PubMed ID: 30621769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A non-proliferative role of pyrimidine metabolism in cancer.
    Siddiqui A; Ceppi P
    Mol Metab; 2020 May; 35():100962. PubMed ID: 32244187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Not just 'immunity': how the microbiota can reshape our approach to cancer immunotherapy.
    Boem F; Nannini G; Amedei A
    Immunotherapy; 2020 Apr; 12(6):407-416. PubMed ID: 32266849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for pancreatic cancer: A long and hopeful journey.
    Xu JW; Wang L; Cheng YG; Zhang GY; Hu SY; Zhou B; Zhan HX
    Cancer Lett; 2018 Jul; 425():143-151. PubMed ID: 29605510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular nucleosides and nucleotides as immunomodulators.
    Kepp O; Loos F; Liu P; Kroemer G
    Immunol Rev; 2017 Nov; 280(1):83-92. PubMed ID: 29027229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy.
    Oberholtzer N; Quinn KM; Chakraborty P; Mehrotra S
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
    Bader JE; Voss K; Rathmell JC
    Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Status and Future Directions of Bacteria-Based Immunotherapy.
    Tang Q; Peng X; Xu B; Zhou X; Chen J; Cheng L
    Front Immunol; 2022; 13():911783. PubMed ID: 35757741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.